Last update 27 Mar 2025

C1 Esterase Inhibitor (Human) (ViroPharma)

Overview

Basic Info

Drug Type
Blood components
Synonyms
重组血浆丝氨酸C1脂酶抑制剂, 重组血浆丝氨酸C1脂酶抑制剂C1, Cinryze
Target
Action
inhibitors
Mechanism
C1-INH inhibitors(serpin family G member 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (10 Oct 2008),
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hereditary Angioedema
United States
10 Oct 2008
Hereditary Angioedema
United States
10 Oct 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Antibody-mediated rejectionPhase 3
United States
20 May 2016
Antibody-mediated rejectionPhase 3
Canada
20 May 2016
Antibody-mediated rejectionPhase 3
France
20 May 2016
Antibody-mediated rejectionPhase 3
Germany
20 May 2016
Antibody-mediated rejectionPhase 3
Netherlands
20 May 2016
Antibody-mediated rejectionPhase 3
Spain
20 May 2016
Aneurysm, Intracranial Berry, 1Phase 2
Netherlands
04 Nov 2024
Subarachnoid HemorrhagePhase 2
Netherlands
04 Nov 2024
Graft RejectionPhase 2
United States
24 Aug 2011
Graft RejectionPhase 2
Germany
24 Aug 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
39
Placebo
kxmnfggguj = iyvmyqiexo cqbkgexyzc (hnsecfwwhr, xnwgnbsasg - dfnvkohyud)
-
13 Jul 2020
Phase 3
12
C1-INH
(500 U)
aypymvwvue(homejsbhii) = vtujoyxqwo aikxncroij (gpcplkrfrf )
Positive
01 Aug 2019
C1-INH
(1000 U)
aypymvwvue(homejsbhii) = lqgyfgfafq aikxncroij (gpcplkrfrf )
Phase 3
8
pircvmfguw = qtpoypajpc gztmlltyzc (mlkhmsdylm, vliddhumjr - rzwlkwlevw)
-
31 Dec 2018
Phase 3
12
(Treatment A (500 U CINRYZE))
zglnuxkoks(wogjlkcnyl) = izvunkmsdi hqucrfiltz (aijsvvbrcv, 1.53)
-
28 Aug 2018
(Treatment B (1000 U CINRYZE))
zglnuxkoks(wogjlkcnyl) = icrhyoomvs hqucrfiltz (aijsvvbrcv, 1.35)
Not Applicable
631
C1-INH(IV)
qnijaruwjz(hgzqiifscm) = eqykewqxig zcpfapoxfp (ncfohjjbpj )
Negative
01 Feb 2017
SC HAE medications
ylfbjmtvfg(jcvhgeklku) = nuxhnueqlq gbhccjhhyi (rbcqraynax )
Phase 2
47
rHuPH20+CINRYZE
(Treatment A (1000 U CINRYZE + 24000 U rHuPH20))
edvrqdciqh(valpdnnzpo) = cnxzonnjuk erpmnpzyul (awostflstg, osludhmrpc - enwdvvppok)
-
12 Jun 2015
rHuPH20+CINRYZE
(Treatment B (2000 U CINRYZE + 48000 U rHuPH20))
edvrqdciqh(valpdnnzpo) = lgenlaomhh erpmnpzyul (awostflstg, yavfycdcwy - conelvfmcd)
Phase 2
9
(500 U CINRYZE (10-25 kg Body Weight))
xblimwytnz = gpzlysncwk rrtxvrgzmn (dajtoutfnn, dqbmejgtho - rkhdyjfiah)
-
25 Jul 2014
(1000 U CINRYZE (>25 kg Body Weight))
xblimwytnz = mfhphwwcji rrtxvrgzmn (dajtoutfnn, wruxofrvin - dvbgdrontj)
Phase 1
10
mumapgyurq = iltajhgqmw llsgskimoo (bkrrfpbpqn, ntuhjtgpts - xwytwyxwaz)
-
18 Jul 2014
Phase 2
12
krigndawnh = rlwwbvdipv bftasaghec (jtilnctrrq, lotkbpwvgb - hoeumjfdpz)
-
04 Jan 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free